CompanyGraph
Hubei Biocause Heilen Pharmaceutical Co., Ltd.
301211 · SZSE · China
biocause.comFinancials as of FY2025
What stands out
- Earnings significantly exceed cash generation
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.86%
Annual Rate
CNY 0.12Paid semi-annual
Payout Ratio
215.5%High
Payback Period
53.7 yr
Last Ex-Dividend
Jun 12, 2026
The reported statements, read against the company's own industry.
What stands out
- Earnings significantly exceed cash generation
Financials view
Market Capitalization
6.07BCNY901.80M · vs all stocks (USD)
Trailing P/E
155.50xRevenue (TTM)
459.02MCNY68.17M · vs all stocks (USD)
Profit Margin
7.36%Beta
0.5140xvs all stocks
52-Week Change
7.15%vs all stocks
Forward Annual Dividend Yield
0.86%vs all stocks
Market Capitalization
6.07BCNY901.80M · vs all stocks (USD)
Enterprise Value
3.66BCNY543.19M · vs all stocks (USD)
Trailing P/E
155.50xPrice to Sales (TTM)
11.32xPrice to Book (MRQ)
2.28xEnterprise to Revenue
7.97xEnterprise to EBITDA
77.95xGross Margin
20.93%Profit Margin
7.36%Operating Margin
2.35%Return on Assets (TTM)
0.01%Return on Equity (TTM)
1.47%Revenue (TTM)
459.02MCNY68.17M · vs all stocks (USD)
Revenue per Share (TTM)
1.09CNYUpdated Aug 20, 2026Quarterly Revenue Growth
5.00%Gross Profit (TTM)
94.66MCNY14.06M · vs all stocks (USD)
EBITDA (TTM)
41.38MCNY6.15M · vs all stocks (USD)
Net Income (TTM)
33.80MCNY5.02M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-10.70%Operating Cash Flow (TTM)
-968.98KCNY-143.91K · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-48.78MCNY-7.24M · vs all stocks (USD)
Forward Annual Dividend Rate
0.1200CNYUpdated Aug 20, 2026Forward Annual Dividend Yield
0.86%vs all stocks
Trailing Annual Dividend Rate
0.2324CNYUpdated Aug 20, 2026Trailing Annual Dividend Yield
1.67%vs all stocks
Payout Ratio
215.52%Revenue
453.31MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
353.10MCNYFY2025 · Dec 31, 2025Gross Profit
100.20MCNYFY2025 · Dec 31, 2025Operating Income
7.41MCNY1.10M · vs all stocks (USD)
Pre-tax Income
41.26MCNYFY2025 · Dec 31, 2025Income Tax Expense
6.35MCNYFY2025 · Dec 31, 2025Net Income
34.91MCNYFY2025 · Dec 31, 2025EBIT
41.44MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
76.41MCNYFY2025 · Dec 31, 2025Research & Development
25.18MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
31.21MCNYFY2025 · Dec 31, 2025Other Operating Expenses
6.91MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
11.94MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
179.05KCNYFY2025 · Dec 31, 2025Net Income from Continuing Operations
34.91MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
33.98MCNYFY2025 · Dec 31, 2025Free Cash Flow
-18.31MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
438.76MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
34.91MCNYFY2025 · Dec 31, 2025Other Non-cash Items
1.61MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-14.14MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
11.61MCNYFY2025 · Dec 31, 2025Capital Expenditures
-52.30MCNYFY2025 · Dec 31, 2025Purchase of Investments
-475.71MCNYFY2025 · Dec 31, 2025Sale of Investments
490.72MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-37.29MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-72.00MCNYFY2025 · Dec 31, 2025Other Financing Charges
-1.40MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-73.40MCNYFY2025 · Dec 31, 2025Shares Outstanding
417.60MSharesUpdated Aug 20, 2026Float Shares
167.32MSharesUpdated Aug 20, 2026% Held by Insiders
73.58%vs all stocks
% Held by Institutions
0.20%vs all stocks
Total Cash (MRQ)
1.54BCNY228.72M · vs all stocks (USD)
Total Cash per Share (MRQ)
3.69CNYUpdated Aug 20, 2026Total Debt (MRQ)
2.35MCNY348.86K · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0010xCurrent Ratio (MRQ)
17.18xBook Value per Share (MRQ)
5.47CNYUpdated Aug 20, 2026Total Assets
2.40BCNY356.73M · vs all stocks (USD)
Total Current Assets
1.79BCNYFY2025 · Dec 31, 2025Total Liabilities
128.65MCNYFY2025 · Dec 31, 2025Total Non-current Assets
610.27MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
14.10MCNYFY2025 · Dec 31, 2025Total Current Liabilities
114.55MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
447.66MCNYFY2025 · Dec 31, 2025Other Short-term Investments
1.11BCNYFY2025 · Dec 31, 2025Accounts Receivable
63.47MCNYFY2025 · Dec 31, 2025Inventory
122.68MCNYFY2025 · Dec 31, 2025Accounts Payable
72.27MCNYFY2025 · Dec 31, 2025Short-term Debt
1.13MCNYFY2025 · Dec 31, 2025Other Current Liabilities
11.95MCNYFY2025 · Dec 31, 2025Long-term Debt
2.01MCNYFY2025 · Dec 31, 2025Common Stock (Book)
417.60MCNYFY2025 · Dec 31, 2025Retained Earnings
167.37MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
2.27BCNY337.62M · vs all stocks (USD)
52-Week Low
9.01CNYUpdated Aug 20, 202652-Week High
16.95CNYUpdated Aug 20, 202652-Week Change
7.15%vs all stocks
Beta
0.5140xvs all stocks
50-Day MA
10.98CNYUpdated Aug 20, 2026200-Day MA
12.16CNYUpdated Aug 20, 2026Avg 10-Day Volume
12.57MSharesUpdated Aug 20, 2026Avg 30-Day Volume
14.96MSharesUpdated Aug 20, 2026Diluted EPS (TTM)
0.0800CNYUpdated Aug 20, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Earnings significantly exceed cash generationSignificant
Net Income (USD, TTM): 5,020,359.182Operating Cash Flow (USD, TTM): -143,913.058
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Shandong Wit Dyne Health Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
LB Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
China Isotope & Radiation Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
Hangzhou Biotest Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
DNA Link Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Wuhan Keqian Biology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Wanbangde Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Cloudbreak Pharma Inc.
Tier 1ProductionApproval-Gated PipelineRule
Wuhan Huakang Century Medicine Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
InMode Ltd.
Tier 1ProductionApproval-Gated PipelineRule